Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Azenta (NASDAQ:AZTA) Stock Surges 10% to a 52-Week High as Momentum Builds After Stronger Fiscal Third-Quarter Results

Azenta (NASDAQ:AZTA), the Burlington, Massachusetts life sciences company that provides sample storage, management and genomic services, is surging in Monday's session. The shares are up 10.37% at $42.77 on volume well above average, pressing against the 52-week high near $43, while the broader healthcare …

Nitish Kishor | 05 October 2026

Genmab (NASDAQ:GMAB) Stock Jumps 12%: Epcoritamab Plus R-CHOP Cuts Progression Risk 51% in Phase 3 DLBCL Trial

Genmab (NASDAQ:GMAB), the Copenhagen-based antibody company whose science powers eight approved medicines, is surging in Monday's session. The shares are up 11.63% at $38.79 on volume more than four times average, while the healthcare sector is little changed.

Nitish Kishor | 05 October 2026

Humana (NYSE:HUM) Stock Rises 4% as Medicare Advantage Repricing and a Brokerage Upgrade Lift Shares Ahead of November 6 Earnings

Humana (NYSE:HUM), the Louisville, Kentucky health insurer best known for its Medicare Advantage franchise, is climbing in Monday's session. The shares are up 3.93% at $403.64, outpacing the sector and its peers, with the broader market near record highs.

Nitish Kishor | 05 October 2026

Which bee-venom biotech worth about USD 6 million is whipsawing on blockchain deals and a new CFO paid USD 60,000 a year?

Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) disclosed in an 8-K that Erick Frim, interim chief financial officer, resigned on September 29, 2026, effective immediately, with no disagreement over operations, policies or practices. The board appointed Eric Sherb, a certified publicAccountantwho previously served as fractional CFO ofSubsidiaryMindWave …

Nitish Kishor | 05 October 2026

Why did a biotech with positive Phase 2 hive data in 54 percent of patients fall 11.3 percent to USD 22.68 two weeks after the readout?

Cue Biopharma (NASDAQ:CUE) fell 11.3 percent to USD 22.68 on October 5 in published market data, with trading value well below its typical session. Peers also weakened, with Nkarta down about 3.9 percent and Coherus Oncology about 3.5 percent, so part of the move …

Nitish Kishor | 05 October 2026

NewGenIvf Group (NASDAQ:NIVF) Stock: Why It Was Among the Day's Most-Traded Stocks With No News

Some of Friday's busiest trading onWall Streethad nothing to do with Nvidia or Tesla. It happened in a stock that closed at about 13 cents. NewGenIvf Group, which trades as NASDAQ:NIVF, finished the session at $0.13 after a sharp jump, with roughly 258.7 million …

Nitish Kishor | 05 October 2026

Kodiak Sciences (NASDAQ:KOD) Stock: Why Apparent Profit-Taking Followed a September Surge

Kodiak Sciences (NASDAQ:KOD) slipped on Friday with no new company news, as traders appeared to lock in gains after the eye-disease drug developer nearly tripled in a month. Shares fell on Friday, October 2, as traders appeared to take profits after a spectacular run …

Nitish Kishor | 05 October 2026

UnitedHealth Group (NYSE:UNH) Stock: Why It Edged Higher as Health Care Fell

UnitedHealth Group (NYSE:UNH) shares edged higher on Friday, October 2, a small but notable outlier on a day when health care was the only one of the 11 S&P 500 sectors to finish in the red. No company-specific news was found for UnitedHealth. The …

Nitish Kishor | 05 October 2026

Anteris Technologies Global (NASDAQ:AVR) Stock: Why a Major Holder Adding to Its Stake Gapped Shares Higher

Anteris Technologies Global (NASDAQ:AVR) opened higher after regulatory filings showed one of its large shareholders, L1 Capital, bought more shares earlier in the week. The stock gapped higher at the open on Friday, October 2, after disclosed filings showed that major holder L1 Capital …

Nitish Kishor | 05 October 2026

BioCardia (NASDAQ:BCDA) Stock: Why Refiling Its Helix Catheter Submission With the FDA Lifted Shares

BioCardia (NASDAQ:BCDA) rose in premarket trading after filing a revised submission with US regulators for its Helix catheter, a device it uses to deliver therapies directly into the heart. Shares jumped in early trading on Friday, October 2, after the company said it filed …

Nitish Kishor | 05 October 2026
Support

Hi! How can we help you today?

Loading…